Clinical Trials Browser

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Phase 1/2 Recruiting

31 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Phase 2/3 Not yet recruiting

87 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Phase EARLY_PHASE1 Recruiting

36 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06668558 2025-09-19

VERDI

Phase 2 Recruiting

29 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05182385 2025-07-25

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Phase 1/2 Active not recruiting

30 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05904106 2024-12-02

VINCENT

Phase 2 Recruiting

146 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Phase 2 Recruiting

67 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04748848 2023-03-02

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Phase 1 Terminated

1 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Phase 2 Unknown

52 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual